

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 28, 2005  
-----

-----  
THE QUIGLEY CORPORATION  
-----

(Exact Name of Registrant as Specified in Charter)

Nevada ----- (State or Other Jurisdiction of Incorporation)	0-21617 ----- (Commission File Number)	23-2577138 ----- (IRS Employer Identification No.)
----------------------------------------------------------------------	-------------------------------------------------	-------------------------------------------------------------

Kells Building, 621 Shady Retreat Road, P.O. Box 1349, Doylestown, PA 18901  
-----

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code (215) 345-0919  
-----

N/A  
-----

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (SEE General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On July 28, 2005, The Quigley Corporation (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2005. The full text of the press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

ITEM 8.01 OTHER EVENTS.

On July 28, 2005, the Company issued a press release providing updates on the status of its pharmaceutical pipeline. The full text of the press release is attached hereto as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit No. -----	Description -----
99.1	Press Release dated July 28, 2005 reporting second quarter ended June 30, 2005 preliminary unaudited earnings and updates on the status of the Company's pharmaceutical pipeline.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE QUIGLEY CORPORATION  
(Registrant)

Date: August 1, 2005

By: /s/ George J. Longo  
-----  
Name: George J. Longo  
Title: Vice President and Chief Financial Officer

QUIGLEY

Carl Hymans  
G.S. Schwartz & Co.  
(212) 725-4500  
carlh@schwartz.com  
-----

Carl Fonash  
The Quigley Corporation  
(267) 880-1111  
fonash@quigleyco.com

QUIGLEY REPORTS SECOND QUARTER RESULTS

--NET SALES INCREASED 28%; COLD REMEDY SEGMENT NET SALES UP 36%--

DOYLESTOWN, PA. - JULY 28, 2005 - THE QUIGLEY CORPORATION (NASDAQ: QGLY) today reported net sales of \$8.8 million for the second quarter of 2005, a 28.2% increase over the \$6.9 million reported for the same period in 2004. For the six months ended June 30, 2005, net sales were \$20.6 million, a 24.8% increase over the \$16.5 million reported for the same period in 2004.

Net sales of the Company's Cold Remedy segment increased 36.4% for the second quarter of 2005 compared to 2004. Overall net sales of the Health and Wellness segment remained relatively unchanged for the second quarter of 2005 compared to 2004. The segment's European sales increased 39.7% and were offset by a decrease in the domestic Health and Wellness operation, which was due to a decline in the number of active domestic independent representatives. Net sales also reflects \$1.4 million generated from the Company's Contract Manufacturing segment which has no comparable amount in 2004, as operations of this segment were part of the fourth quarter 2004 acquisition of the facilities that manufactured COLD-EEZE(R).

The increase in net sales for the six months reflects a 38.8% increase in the Company's Cold Remedy segment and a 4.5% decrease in the Health and Wellness segment.

The Company's Cold Remedy net sales continued to far outpace the growth in its category as the further expansion of the Cold Remedy segment reflects the success of strategic advertising and marketing initiatives; new product extensions of COLD-EEZE(R); and a notable increase in consumer acceptance, as reflected in a recent analysis demonstrating an expanded household penetration.

The Company's Health and Wellness European sales for the six months increased 28.7% reflecting the expansion of international distribution. The rise in international distribution partially offset a decrease in domestic Health and Wellness segment sales. Net sales for 2005 also reflect \$2.4 million from the Company's Contract Manufacturing segment, which has no comparable amount in 2004.

Guy J. Quigley, Chairman, President and Chief Executive Officer said, "We are generally pleased with our overall results which include increases in sales for the quarter and six-month periods, particularly as the second quarter is our seasonally weakest period for COLD-EEZE(R) sales. The increase in sales reflects the success of ongoing initiatives to generate greater market share for our COLD-EEZE(R) Cold Remedy products and the expansion of the European Health and Wellness segment. We remain well positioned to continue to generate increasing sales of our core COLD-EEZE(R) products and expand its market penetration."

Net loss for the second quarter ended June 30, 2005 was \$1.8 million, or (\$0.15) per share compared to a net loss of \$912,000, or (\$0.08) per share, for the same period last year. Net loss for the six-months ended June 30, 2005 was \$1.9 million, or (\$0.17) per share, compared to a net loss of \$1.7 million, or (\$0.15) per share, for the same period last year. Net loss for the six-months ended June 30, 2005 and 2004 is principally attributed to research and development costs of \$1.9 million and \$1.8 million, respectively.

Gross profit percentage margins for the Cold Remedy segment for the quarter were consistent with margins attained for the comparable period in 2004. The gross profit percentage margins for the Health and Wellness declined due to inventory obsolescence charges. Gross profit gains of the Cold Remedy segment for the quarter and six months ended June 30, 2005 were offset by decreases in Health and Wellness gross profit including substantially lower gross profit margins for the Contract Manufacturing segment than other operating segments.

The net loss for the quarter and six months ended June 30, 2005 increased as compared with the same periods last year, due to increased operating costs of all business segments, including non-manufacturing operating costs of the contract manufacturing segment that impacted current operations rather than being carried as inventory. Net loss for the six months was in line with the same period last year.

No tax benefits to reduce losses are provided for the quarter and six month periods ended June 30, 2005 and 2004, as the Company is in a net operating loss carry-forward position from the cumulative effect of deductions attributed to options, warrants and unrestricted stock from previous year's taxable income.

Mr. Quigley continued, "During the quarter we announced several important developments in our pharmaceutical segment including the completion of a double-blind placebo controlled study of our QR-340 Scar Formula in which initial results demonstrated that the formula was safe, effective and outperformed Mederma(R), the top selling scar appearance formula in the

commercial marketplace.

In addition, a series of In-Vivo (animal model) inflammation studies of our potential broad-spectrum anti-inflammatory, all natural, botanical compound, QR440 demonstrated a significant effect on both sterile and immune mediated inflammation. QR440 has the potential to meet the significant need for safe and effective therapies for patients with rheumatoid arthritis and other inflammatory disorders," concluded Mr. Quigley.

The following is a list of other formulations currently in the Quigley Pharma pipeline:

DIABETIC NEUROPATHY - QR333: A patented topical compound that extends through March 2021 is being tested to treat people that suffer from diabetic peripheral neuropathy, which can affect 60 to 70 percent of the 15.7 million diabetics in the country.

SYSTEMIC RADIATION - QR336: A patented compound that extends through November 2021 is being investigated to potentially reduce the effects of radiation exposure.

ARTHRITIS - QR440: A patented naturally-derived compound that extends through April 2023 is being developed for the treatment of arthritis and related inflammatory disorders as arthritis can afflict 40 million people in the US; 350 million worldwide.

INFLUENZA A - QR435: A test compound with potentially broad anti-viral properties for applications such as Influenza A&B in an intranasal delivery.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will grant an Investigational New Drug ("IND") or take any other action to allow its formulations to be studied or marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound, referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well-controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

The Quigley Corporation (Nasdaq: QGLY, <http://www.Quigleyco.com>) is a leading developer and marketer of diversified health products including the COLD-EEZE(R) family of patented zinc gluconate glycine (ZIGG(TM)) lozenges and sugar free tablets. COLD-EEZE is the only (ZIGG) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (<http://www.QuigleyPharma.com>), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

#### FORWARD-LOOKING STATEMENTS

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

(Tables Follow)

#### CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

The following represents condensed financial data (in thousands) except per share data:

	Three-Months Ended June 30, 2005 (\$)	Three-Months Ended June 30, 2004 (\$)	Six-Months Ended June 30, 2005 (\$)	Six-Months Ended June 30, 2004 (\$)
Net Sales	8,844	6,901	20,597	16,507
Gross profit	3,034	2,777	8,736	7,297
Sales & marketing expenses	1,067	835	2,902	2,458

Administrative expenses	2,987	2,055	5,981	4,805
Research & development	841	821	1,909	1,768
Income taxes (Benefit)	--	--	--	--
Net loss	(1,790)	(912)	(1,945)	(1,694)
Diluted loss per share:				
Net loss	(\$ 0.15)	(\$ 0.08)	(\$ 0.17)	(\$ 0.15)
Diluted weighted average common shares outstanding:	11,655,995	11,512,092	11,655,396	11,511,390

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

The following represents condensed financial data (in thousands) at June 30, 2005 and December 31, 2004:

	2005 (\$)	2004 (\$)
	-----	-----
Cash & cash equivalents	13,979	14,366
Accounts receivable, net	1,623	6,376
Inventory	3,761	3,455
Total current assets	20,297	24,961
Total assets	26,398	31,530
Total current liabilities	5,095	7,109
Long-term debt	1,250	2,464
Total stockholders' equity	19,997	21,902